American Society of Hirudotherapy

Time to Reconsidering the Potential Role of Leech Salivary Proteins in Medicine: Type-II Kounis Syndrome Triggered by Leech Bite

Research article published in Pakistan journal of medical sciences (2025)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Case reportSalivary PharmacologyTas B et al. · Pakistan journal of medical sciences, 2025

Abstract

Kounis syndrome also known as allergic myocardial infarction, represents the simultaneous occurrence of acute coronary syndromes with allergic or hypersensitivity reactions. We present a case of a 58-years-old male who developed anaphylaxis following a leech bite, leading to myocardial infarction despite the absence of prior allergic history. He was entubated and cardiopulmonary resusciation had been performed for 10 minutes. The patient was successfully resuscitated and Intravenous antihistamine, prednisolone and adrenaline were given. The patient was stabilized and transferred to the intensive care unit and coronary angiography was performed, which revealed a 90% stenosis in the circumflex coronary artery. A stent was successfully implanted in the affected artery. This report emphasizes the complexity of diagnosing and managing Type-II Kounis syndrome and highlights the need for increased clinical awareness.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeCase ReportsJournal Article

Summary

Time to Reconsidering the Potential Role of Leech Salivary Proteins in Medicine: Type-II Kounis Syndrome Triggered by Leech Bite.

Why This Matters for Hirudotherapy

This case report describes a 58-year-old male with no prior allergic history who developed anaphylaxis and myocardial infarction (Type-II Kounis syndrome) following a leech bite, requiring intubation, cardiopulmonary resuscitation, antihistamines, corticosteroid, and adrenaline, followed by coronary stenting for a 90% circumflex artery stenosis. For ASH's domain, this is relevant as a rare but serious adverse event temporally linked to leech exposure, highlighting safety considerations in hirudotherapy. CAVEAT: This is a single case report and does not establish incidence or causation beyond temporal association; the abstract does not specify the leech species, setting (wild vs therapeutic), or secretome components involved, so generalizability to controlled hirudotherapy is limited.

Citation

Time to Reconsidering the Potential Role of Leech Salivary Proteins in Medicine: Type-II Kounis Syndrome Triggered by Leech Bite

Tas B et al. · Pakistan journal of medical sciences, 2025

Added to ASH library: May 27, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.